4Dmedical Limited
4DX.ASXHealth Care
Medical imaging software and hardware provider
Market Data
$3.890
+0.2%$2.0B
-100000.0x
$-0.336
0.00%
0.0%
Latest Earnings
Appendix 4D and FY26 Half Year Report
27 February 2026
4DMedical delivered a transformational H1 FY26 with FDA clearance and CMS reimbursement for its breakthrough CT:VQ™ technology, rapid adoption by leading U.S. academic medical centers, and a $150m institutional placement. Despite revenue remaining flat at $2.9m, underlying SaaS revenue grew 31% YoY, scan production surged 110% to 151,905 units, and operational efficiency improved with adjusted net loss down 18% to $16.2m, positioning the company for significant commercialisation acceleration. Key points: FDA clearance (Sept 2025) and immediate CMS reimbursement at US$650.50/scan for CT:VQ™—world's first non-contrast CT-based ventilation-perfusion imaging, addressing a US$1.1B annual addressable market in the U.S. alone; Rapid adoption by 5 leading U.S. academic medical centers (Stanford, Cleveland Clinic, UC San Diego, University of Miami, University of Chicago) within 4 months of FDA clearance, establishing critical reference sites; Philips distribution partnership for North America with ~A$15m underwritten minimum revenue commitment over CY26–CY27, unlocking access to ~14,500 U.S. CT scanners
Recent Announcements
Becoming a substantial holder
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) became a substantial holder (5.0476%).
Ceasing to be a substantial holder
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) ceased to be a substantial holder.
Becoming a substantial holder
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) became a substantial holder (5.0642%).
Ceasing to be a substantial holder
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) ceased to be a substantial holder.
Becoming a substantial holder
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) became a substantial holder (5.3553%).
Ceasing to be a substantial holder
State Street Corporation ceased to be a substantial holder.
Becoming a substantial holder
State Street Corporation became a substantial holder (5.01%).
Appendix 4D and FY26 Half Year Report
4DMedical delivered a transformational H1 FY26 with FDA clearance and CMS reimbursement for its breakthrough CT:VQ™ technology, rapid adoption by leading U.S. academic medical centers, and a $150m institutional placement. Despite revenue remaining flat at $2.9m, underlying SaaS revenue grew 31% YoY, scan production surged 110% to 151,905 units, and operational efficiency improved with adjusted net loss down 18% to $16.2m, positioning the company for significant commercialisation acceleration. Key points: FDA clearance (Sept 2025) and immediate CMS reimbursement at US$650.50/scan for CT:VQ™—world's first non-contrast CT-based ventilation-perfusion imaging, addressing a US$1.1B annual addressable market in the U.S. alone; Rapid adoption by 5 leading U.S. academic medical centers (Stanford, Cleveland Clinic, UC San Diego, University of Miami, University of Chicago) within 4 months of FDA clearance, establishing critical reference sites; Philips distribution partnership for North America with ~A$15m underwritten minimum revenue commitment over CY26–CY27, unlocking access to ~14,500 U.S. CT scanners
Get real-time alerts for 4DX
Receive AI-powered earnings summaries and instant notifications when 4Dmedical Limited releases results.
Register Free